Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders. The